Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 681-684    DOI: 10.31083/j.ejgo.2020.05.5401
Original Research Previous articles | Next articles
Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population
Michelle F. Benoit1, *(), Kristy K. Ward1
1Gynecologic Oncology, Kaiser Permanente Washington, United States
Download:  PDF(540KB)  ( 95 ) Full text   ( 12 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: We sought to compare two intraoperative uterine cancer normograms for prediction of lymph node (LN) metastasis. We used the widely known Mayo criteria, comparing it to an algorithm provided by Koskas et al. to predict likelihood of LN metastasis. Design: 490 uterine cancer patients from a single practice provider were included in the review. Data was abstracted to include age, race, stage, tumor size, grade, histologic subtype, depth of invasion, cervical involvement, lymphovascular space involvement (LVSI), and microsatellite instability (MSI). Patient comorbidities were analyzed to include body mass index (BMI), diabetes, and hypertension. Laboratories for these comorbidities were included. Those patients staged 1, 2, and 3 were included in final analysis. Results: The receiver operator curve (ROC) for the Koskas normogram was 0.78 when 4% was used as the cutoff for LN metastasis, with a sensitivity of 78% and specificity of 60%. When a 5% cutoff was used, the ROC was 0.71. For every percentage point that the French score rose, the chance of being LN positive increased by 0.8% (p < 0.001). The three point Mayo criteria odds ratio (OR) was 7.4 and the ROC was 0.57. Lymph node metastasis also correlated with MSI as seen on immunohistochemistry (IHC) testing. Conclusions: The Koskas normogram provided a better predictive algorithm for risk assessment of LN metastasis. Our results are comparable with those previously published by Koskas et al. providing an external validation of this normogram previously used in an European population. These intraoperative variables can be incorporated into real time risk assessment for LN metastasis and operative decision making. Mayo criteria, not using tumor size, could spare an additional 40% of patients an unnecessary LND compared to standard 3 point Mayo criteria--with better predictive value.
Key words:  Uterine cancer      Endometrial cancer      Lymph node metastasis      Mayo      Algorithm      Prediction     
Submitted:  24 October 2019      Accepted:  17 April 2020      Published:  15 October 2020     
*Corresponding Author(s):  MICHELLE BENOIT     E-mail:  benoitmf1@yahoo.com

Cite this article: 

Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5401     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/681

[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[3] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[4] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[5] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[6] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[7] J.Y. Chen, Z.Q. Wang, S.C. Liang, H.Y. Hou, D.B. Chen, J.L. Wang. Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 408-414.
[8] J. Feng, J. Wu, M. Zhang, J. Wang, K. Chen, X. Li, J. Xie, J. Zhang, C. Wang. Oleic acid promotes the development of endometrial cancer by up-regulating KLF4 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 432-438.
[9] S. Liu, F. Ruan, M. Shi, Y. Liu, W. Li, B. Bi, H. Wang, W. Lv. Safe fertility-preserving management in a young woman with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 476-479.
[10] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[11] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[12] S. Srdelić Mihalj, V. Čapkun, I. Kuzmić-Prusac. High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 16-22.
[13] Y.-S. Kwon, K. S. Im, S. B. Yoo, W. I. Kim. Two cases of uterus-conserving treatment for early stage endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 145-147.
[14] T. Wada, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 148-150.
[15] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[7] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[8] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[9] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .
[10] E. Yilmaz, E. I. Coskun, C. Koc, N. Sahin, B. Isik, B. Ciplak. Isolated recurrence of early-stage cervical cancer in the abdominal wall with suboptimal surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 485 -487 .